Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unchanged; Company initiates search for successor
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, has decided to leave Teva and has accepted an offer outside the company. Dr. Hughes will remain with Teva through the coming months to support a seamless transition.
Effective immediately, David Gardiner, MD, Head of Innovative Medicines & Clinical Development, will serve as transition lead for R&D, reporting directly to Teva's President and Chief Executive Officer, Richard Francis, until a permanent successor is named. Teva is initiating a comprehensive search for a successor beginning immediately.
“Eric has made critical contributions to Teva and to the transformation of our R&D organization,” said Richard Francis, President and CEO of Teva. “He has helped build the pipeline, capabilities, and organization we presented at R&D Day last week and leaves Teva well positioned for its next chapter. Our strategy, priorities and expectations have not changed, and our focus remains on executing against the commitments we have made and continuing the momentum across our innovative pipeline.”
“I am incredibly proud of what our R&D organization accomplished to establish Teva as a truly innovative biopharma company and of the strong team we built,” said Dr. Hughes. “The progress we shared at R&D Day reflects the strength and depth of this organization and the exceptional science we developed together. I am deeply grateful to the entire team for their dedication, talent and partnership. It has been a privilege to lead them.”
Teva's R&D strategy and priorities remain unchanged, and the company remains focused on delivering on the commitments outlined in its November 11th R&D Day, including its ambition to generate $6–7 billion in innovative medicines revenue by 2030.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All in for Better Health. To learn more about how, visit www.tevapharm.com.
Teva Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to attract, hire, integrate and retain highly skilled personnel; our ability to become a high-velocity biopharmaceutical company and to achieve the potential revenue growth from innovative medicines; our ability to deliver on the ambitions and targets for the development of our pipeline assets; our ability to achieve the other ambitions and targets discussed in our R&D Day presentation; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all; our business and operations in general, including: the impact of global geopolitical, economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and our exposure to changes in international trade policies; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries: TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries: TevaIR@Tevapharm.com
-
标准互通·全球共生丨2026 RISC-V产业发展大会全球合作特别论坛在澳门举行标准互通·全球共生丨2026 RISC-V产业发展大会全球合作特别论坛在澳门举行2026-11-19
-
科技连接世界丨CAYE Smart X × 铁氮 FeN机器人咖啡师亮相APEC深圳科技连接世界丨CAYE Smart X × 铁氮 FeN机器人咖啡师亮相APEC深圳2026-11-19
-
开辟新思路!杭州的这家量子计算公司在AI for Science领域悄然做了几千万的业务开辟新思路!杭州的这家量子计算公司在AI for Science领域悄然做了几千万的业务2026-11-19
-
康力电梯董事长、总裁朱琳昊出席2026APEC工商领导人峰会康力电梯董事长、总裁朱琳昊出席2026APEC工商领导人峰会2026-11-19
-
全民增收以养老减负回应亿万家庭民生关切减轻养老之重 夯实增收之基——全民增收以养老减负回应亿万家庭民生关切 养老负担,正在进入越来越多普通家庭。 养老金扣除日常生活和慢病用药后,还能剩下多少?2026-11-19
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
锚定健康中国新征程!第一届医药信息传播论坛将于广州启幕
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐
